Cite
HARVARD Citation
Kim, K. et al. (n.d.). A phase II study to evaluate the efficacy of regorafenib in C-KIT mutated metastatic malignant melanoma patients who have progressed on first-line treatment: A Multicenter Trial of Korean Cancer Study Group (UN-14–13). European journal of cancer. pp. S85-S86. [Online].